Literature DB >> 10351144

Effect of intravenous immunoglobulin therapy on plasma complement.

E Wegmüller1.   

Abstract

The effect of the intravenous immunoglobulin preparation (Sandoglobulin) on the complement system and the formation of circulating immune complexes (CIC) was investigated in 10 patients with primary humoral immunodeficiency and in 12 normal volunteers. Infusion of 9 g of the pH4 treated preparation did not show relevant changes in total hemolytic complement activity, plasma levels of C4, C3, and factor B. C3dg fragments, however, increased markedly in some individuals in both groups immediately after infusion. CIC measured by 125 I-C1q binding were not detectable. Furthermore, the initially low C1q concentrations in immune-deficient patients correlated with the pre-infusion IgG levels (p < 0.05) and rose significantly 24 h after therapy (p < 0.001). In contrast, in vitro incubation of the immunoglobulin preparation with normal human serum did not reveal spontaneous anticomplementary activity nor did it lead to formation of immune aggregates. The results indicate that immunoglobulin infusions may moderately activate complement in vivo, as evidenced by increased C3dg fragments; in addition, partial C1q deficiency in hypogammoglobulinemia seems to be related to IgG concentration and can be corrected by immunoglobulin substitution.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10351144     DOI: 10.1016/s0955-3886(98)00055-1

Source DB:  PubMed          Journal:  Transfus Sci        ISSN: 0955-3886


  4 in total

1.  Membranoproliferative glomerulonephritis in a patient with X-linked agammaglobulinemia.

Authors:  Atsunori Yoshino; Masataka Honda; Hirokazu Kanegane; Kazuo Obata; Hiroyoshi Matsukura; Satoru Sakazume; Yasuki Katada; Toshio Miyawaki; Yoshihiko Ueda; Toshiro Nagai
Journal:  Pediatr Nephrol       Date:  2005-11-11       Impact factor: 3.714

2.  Chronic glomerulonephritis associated with IgG subclass deficiency.

Authors:  Koichi Kamei; Atsuko Nakagawa; Yasufumi Otsuka; Makiko Nakayama; Shinichi Kobayashi; Kentaro Matsuoka; Kazumoto Iijima
Journal:  Pediatr Nephrol       Date:  2007-04-17       Impact factor: 3.714

Review 3.  Should development of Alzheimer's disease-specific intravenous immunoglobulin be considered?

Authors:  David A Loeffler
Journal:  J Neuroinflammation       Date:  2014-12-05       Impact factor: 8.322

4.  Tubulointerstitial nephritis complicating IVIG therapy for X-linked agammaglobulinemia.

Authors:  Keisuke Sugimoto; Hitomi Nishi; Tomoki Miyazawa; Norihisa Wada; Akane Izu; Takuji Enya; Mitsuru Okada; Tsukasa Takemura
Journal:  BMC Nephrol       Date:  2014-07-08       Impact factor: 2.388

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.